Video Experimental Relacionado
Updated: May 10, 2026
19:50
Interview: Protein Folding and Studies of Neurodegenerative Diseases
Published on: July 16, 2008
Un debate centenario sobre la agregación de proteínas y la neurodegeneración entra en la clínica
Peter T Lansbury1, Hilal A Lashuel
1Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, 65 Landsdowne Street, Cambridge, Massachusetts 02139, USA. lansbury@rics.bwh.harvard.edu
Nature
|October 20, 2006
Resumen
Los investigadores están investigando el vínculo entre la agregación de proteínas y las enfermedades neurodegenerativas como el Alzheimer. Los ensayos clínicos de fármacos que inhiben la agrupación de proteínas pronto pueden aclarar la causalidad y ofrecer nuevos tratamientos.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- La bioquímica es la bioquímica.
- Patología Patología Patología.
Sus antecedentes:
- Existe una fuerte correlación entre las enfermedades neurodegenerativas y la agregación de proteínas en el cerebro.
- El establecimiento de un vínculo causal definitivo ha sido un desafío debido a la complejidad de estas enfermedades y la dificultad para identificar agregados patógenos específicos.
Objetivo del estudio:
- Explorar la relación entre la agregación de proteínas y las enfermedades neurodegenerativas.
- Evaluar el potencial de los fármacos inhibidores de la agregación en entornos clínicos.
- Para abordar la larga cuestión de la causalidad en los trastornos de plegamiento erróneo de proteínas.
Principales métodos:
- Revisión de la comprensión actual de la agregación de proteínas en condiciones neurodegenerativas.
- Análisis de ensayos clínicos en curso para candidatos a fármacos inhibidores de la agregación.
- Discusión de las implicaciones de los resultados de los ensayos clínicos para la causalidad de la enfermedad.
Principales resultados:
- Si bien un vínculo causal directo sigue siendo elusivo, se han logrado avances significativos en la comprensión de la agregación de proteínas.
- Los fármacos candidatos diseñados para inhibir la agregación de proteínas se encuentran actualmente en evaluación clínica.
- Estos ensayos representan un paso crítico para validar potencialmente el papel de los agregados de proteínas en la patogénesis de la enfermedad.
Conclusiones:
- La inhibición de la agregación de proteínas es prometedora para retrasar la progresión de enfermedades como el Alzheimer y el Parkinson.
- La administración presintomática de estos medicamentos podría reducir significativamente la incidencia de la enfermedad.
- Los ensayos clínicos están preparados para resolver potencialmente el debate sobre el papel causal de la agregación de proteínas en la neurodegeneración.
Videos de Conceptos Relacionados
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...